Understanding new drug paradigms at M1 muscarinic receptors.

了解 M1 毒蕈碱受体的新药物范例。

• 批准号: nhmrc : 1011796
• 负责人: Dr Meritxell Canals
• 金额: $ 22.27万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/understanding-new-drug-muscarinic-receptors/109615
• 关键词: Understanding; new; drug; paradigms; M1

The M1 muscarinic receptor is a brain protein that plays vital roles in memory, and has been implicated in Alzheimer�s and schizophrenia. However, this protein remains poorly targeted by current medications. The current proposal will investigate the mechanisms of action of a new class of more selective M1 receptor drugs. Our studies will generate valuable information that is directly relevant to the pharmaceutical industry and academic drug discovery.

M1毒蕈碱受体是一种在记忆中起重要作用的脑蛋白，与阿尔茨海默氏症和精神分裂症有关。然而，这种蛋白质在目前的药物中仍然缺乏针对性。目前的提案将研究一类新的更具选择性的M1受体药物的作用机制。我们的研究将产生与制药行业和学术药物发现直接相关的有价值的信息。